Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®)
The purpose of this study was evalueted of a long-term treatment outcome in chronic myeloid leukemia (CML) patients in accelerated phase treated with GlivecR and determination of an optimum therapy schedule. 105 patients (men — 46, women — 59) at the age from 15 till 74 years (a median age — 40 year...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/705 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849689904353640448 |
|---|---|
| author | L. A. Antipova S. S. Loria S. V. Semochkin A. G. Rumiantsev |
| author_facet | L. A. Antipova S. S. Loria S. V. Semochkin A. G. Rumiantsev |
| author_sort | L. A. Antipova |
| collection | DOAJ |
| description | The purpose of this study was evalueted of a long-term treatment outcome in chronic myeloid leukemia (CML) patients in accelerated phase treated with GlivecR and determination of an optimum therapy schedule. 105 patients (men — 46, women — 59) at the age from 15 till 74 years (a median age — 40 years) enrolled between 02.2001 and 02.2007 were studied. Treatment started a dose of 600 mg/day. At the insufficient primary therapy response or loss complete hematological and/or complete cytogenetic remission in the course of treatment, dose have been increased to 800 mg/day. In 82 (78.1%) patients complete hematological remissions have been reached. In 44 (41.9%) patients complete cytogenetic response (CR) is received, and in 27 (61.4 %) of them with molecular response: complete — 17 (63%) and major — 10 (27%). 6-year overall survival rate (OS) was 61.9%, 6-year event-free survival rate (EFS) — 30.5%. Achievement of complete CR was a predictor of long longterm survival rate: OS — 95.5% versus 37.7 % (р <0.001). In case of absence CR (n=16) imatinib dose escalation allowed to receive complete CR in 5 (31.25%) and minor — in 4 (25.0%) patients. Loss or absence of complete CR on imatinib therapy not always leads to CML progression: in 18 (17.1 %) patients without complete CR hematological parameters remain normal and there are no signs of disease progression. |
| format | Article |
| id | doaj-art-8a64a829a02c4b24af4840b277e0d19a |
| institution | DOAJ |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2022-11-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-8a64a829a02c4b24af4840b277e0d19a2025-08-20T03:21:28ZrusABV-pressОнкогематология1818-83462413-40232022-11-0101142010.17650/1818-8346-2009-0-1-14-20583Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®)L. A. Antipova0S. S. Loria1S. V. Semochkin2A. G. Rumiantsev3Federal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyThe purpose of this study was evalueted of a long-term treatment outcome in chronic myeloid leukemia (CML) patients in accelerated phase treated with GlivecR and determination of an optimum therapy schedule. 105 patients (men — 46, women — 59) at the age from 15 till 74 years (a median age — 40 years) enrolled between 02.2001 and 02.2007 were studied. Treatment started a dose of 600 mg/day. At the insufficient primary therapy response or loss complete hematological and/or complete cytogenetic remission in the course of treatment, dose have been increased to 800 mg/day. In 82 (78.1%) patients complete hematological remissions have been reached. In 44 (41.9%) patients complete cytogenetic response (CR) is received, and in 27 (61.4 %) of them with molecular response: complete — 17 (63%) and major — 10 (27%). 6-year overall survival rate (OS) was 61.9%, 6-year event-free survival rate (EFS) — 30.5%. Achievement of complete CR was a predictor of long longterm survival rate: OS — 95.5% versus 37.7 % (р <0.001). In case of absence CR (n=16) imatinib dose escalation allowed to receive complete CR in 5 (31.25%) and minor — in 4 (25.0%) patients. Loss or absence of complete CR on imatinib therapy not always leads to CML progression: in 18 (17.1 %) patients without complete CR hematological parameters remain normal and there are no signs of disease progression.https://oncohematology.abvpress.ru/ongm/article/view/705chronic myeloid leukemiaacceleration phaseimatinib |
| spellingShingle | L. A. Antipova S. S. Loria S. V. Semochkin A. G. Rumiantsev Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®) Онкогематология chronic myeloid leukemia acceleration phase imatinib |
| title | Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®) |
| title_full | Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®) |
| title_fullStr | Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®) |
| title_full_unstemmed | Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®) |
| title_short | Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®) |
| title_sort | long term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib glevec r |
| topic | chronic myeloid leukemia acceleration phase imatinib |
| url | https://oncohematology.abvpress.ru/ongm/article/view/705 |
| work_keys_str_mv | AT laantipova longtermtreatmentoutcomeinchronicmyeloidleukemiapatientsinacceleratedphasetreatedwithimatinibglevec AT ssloria longtermtreatmentoutcomeinchronicmyeloidleukemiapatientsinacceleratedphasetreatedwithimatinibglevec AT svsemochkin longtermtreatmentoutcomeinchronicmyeloidleukemiapatientsinacceleratedphasetreatedwithimatinibglevec AT agrumiantsev longtermtreatmentoutcomeinchronicmyeloidleukemiapatientsinacceleratedphasetreatedwithimatinibglevec |